The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Tislelizumab is now approved in nine indications in China
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Amarex Clinical Research guides its client to phase II of FDA trials
New Director supports NASDAQ rule on diversity
Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.
Company hires life science veteran Jessica Cao to join management team
Subscribe To Our Newsletter & Stay Updated
